NeuroSense Therapeutics Limited. is a clinical-stage biotechnology firm that focuses on developing and discovering treatments for neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s. It today announced pricing for its initial public offering. Each unit consists of one ordinary share and a warrant that allows the right to purchase one share at $6.00 per share. This will generate gross proceeds of $12,000,000. NeuroSense also granted the underwriter a 45 day option to purchase an additional 300,000 ordinary shares and/or 300,000. warrants at the initial price. This is in addition to the underwriting discounts, commissions, and underwriting commissions. NeuroSense’s warrants and ordinary shares have been approved to be listed on the Nasdaq Capital Market. They are expected to trade on December 9, 2021, under the ticker symbols “NRSNW” and “NRSNW.”
Maxim Group LLC will be the sole book-running manager of the offering.
NeuroSense is offering all warrants and ordinary shares to be sold in this offering. NeuroSense expects that the offering will close by December 13, 2021. However, it must satisfy all customary closing conditions.
After deducting underwriting discounts, commissions, and estimated offering costs, NeuroSense will receive approximately $9.9million in net proceeds. NeuroSense plans to use the net proceeds of this offering to accelerate the clinical development and treatment of PrimeC for ALS. This includes a Phase IIb trial that is complete and preparations for the initiation a Phase III trial.
A registration statement regarding the securities being offered in this offering was filed with the Securities and Exchange Commission (“the “SEC”) and declared effective December 8, 2021. Only a prospectus is used to make the offering. You can obtain a copy of the final prospectus relating the initial public offering by visiting www.sec.gov. Alternately, you can obtain electronic copies of this prospectus from Maxim Group LLC at 300 Park Avenue 16th Floor, New York City 10022 (212) 895-3745.